[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004108691A1 - Improved production of rosuvastatin calcium salt - Google Patents

Improved production of rosuvastatin calcium salt Download PDF

Info

Publication number
WO2004108691A1
WO2004108691A1 PCT/GB2004/002373 GB2004002373W WO2004108691A1 WO 2004108691 A1 WO2004108691 A1 WO 2004108691A1 GB 2004002373 W GB2004002373 W GB 2004002373W WO 2004108691 A1 WO2004108691 A1 WO 2004108691A1
Authority
WO
WIPO (PCT)
Prior art keywords
isopropyl
calcium salt
solution
pyrimidin
fluorophenyl
Prior art date
Application number
PCT/GB2004/002373
Other languages
French (fr)
Inventor
Jeffrey Norman Crabb
John Horbury
Nigel Philip Taylor
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33512687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004108691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0410922A priority Critical patent/BRPI0410922B8/en
Priority to KR1020057023329A priority patent/KR101099934B1/en
Priority to JP2006508394A priority patent/JP4651615B2/en
Priority to AU2004245291A priority patent/AU2004245291B2/en
Priority to NZ543962A priority patent/NZ543962A/en
Priority to CA2527314A priority patent/CA2527314C/en
Priority to MXPA05013128A priority patent/MXPA05013128A/en
Priority to AT04735910T priority patent/ATE464297T1/en
Priority to US10/558,390 priority patent/US8063213B2/en
Priority to DE602004026576T priority patent/DE602004026576D1/en
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Priority to EP04735910A priority patent/EP1633727B1/en
Publication of WO2004108691A1 publication Critical patent/WO2004108691A1/en
Priority to IL172075A priority patent/IL172075A/en
Priority to NO20055730A priority patent/NO332971B1/en
Priority to IS8217A priority patent/IS2751B/en
Priority to HK06107580.5A priority patent/HK1087405A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention concerns improvements to a chemical process, particularly a chemical process for manufacture of (£)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (1) (illustrated below), which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.
  • the sodium salt (2) and calcium salt (1) of compound (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid (hereinafter referred to as the 'Agent') were disclosed in European Patent 0521471.
  • This patent also describes a process for the synthesis of the calcium salt (1), via the sodium salt (2), as shown in Scheme 1 below. The calcium salt thus formed is then collected and dried and may be processed further as required.
  • Suitable solvents for step a) are in general any water miscible organic solvent; for example solvents such as acetonitrile and acetone.
  • a preferred solvent is acetonitrile.
  • Suitable aqueous acids are acids whose calcium salt is water soluble so that it is not precipitated in Step f).
  • the aqueous acid is hydrochloric acid.
  • the aqueous hydrochloric acid is approximately 0.1M.
  • the aqueous hydrochloric acid is ⁇ about 0.1M.
  • the aqueous hydrochloric acid is ⁇ 0.05M, for example 0.02M.
  • reaction of the (l-6C)alkyl ester of the Agent with aqueous acid is carried out between 30 and 50°C, conveniently between 35 and 40°C.
  • the (l-6C)alkylester of the Agent dissolved in acetonitrile at 35°C is reacted with aqueous hydrochloric acid at 35 °C. .
  • Suitable (l-6C)alkyl esters of the Agent are, for example methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, pentyl or hexyl esters.
  • BEM is a preferred example of a (1- 6C)alkyl ester of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • B ⁇ M may be made by analogous processes, as illustrated in the Examples hereinafter.
  • Step b) may be carried out at a temperature of between approximately 10°C and approximately 40°C. Conveniently, step b) is carried out at ambient temperature, which will generally be understood to mean 20-25 °C, conveniently approximately 25 °C.
  • aqueous alkali metal hydroxide is aqueous potassium hydroxide or aqueous sodium hydroxide.
  • the aqueous alkali metal hydroxide is sodium hydroxide.
  • the aqueous sodium hydroxide is about IM and sufficient quantity is added to form the sodium salt (2).
  • the sodium salt (2) is not isolated and that the product of step b) is an aqueous sodium salt solution. It will also be appreciated that this aqueous sodium salt solution also contains acetonitrile.
  • the aqueous alkali metal salt solution may be washed with toluene, or another suitable organic solvent to remove unreacted (l-6C)alkyl ester of the Agent, such as BEM (3), or other unwanted minor components if required, prior to carrying out step c).
  • Suitable organic solvents for this washing step are in general organic solvents which are immiscible in water but miscible with the water miscible organic solvent used in step a).
  • suitable organic solvents for the washing step are ester, ether and hydrocarbon solvents known in the art. Examples of such suitable solvents are xylene (hydrocarbon solvent), methyl-t-butylether (MTBE) (ether solvent) and ethyl acetate (ester solvent).
  • the toluene or other suitable organic solvent may conveniently be removed from the process by phase separation. Any solvent remaining after phase separation may be removed in Step d).
  • the solvent is toluene.
  • the aqueous alkali metal salt is an aqueous sodium salt.
  • the aqueous sodium salt solution is washed with a suitable organic solvent.
  • the aqueous sodium salt solution is washed with toluene, xylene, MTBE or ethyl acetate.
  • the aqueous sodium salt solution is washed with toluene or xylene.
  • the aqueous sodium salt solution is washed with toluene.
  • the aqueous sodium salt solution is washed with MTBE.
  • the aqueous sodium salt solution is washed with ethyl acetate.
  • step b) the aqueous sodium salt solution is not washed with a suitable organic solvent.
  • the aqueous alkali metal hydroxide is potassium hydroxide. It will be appreciated that in this embodiment, the potassium salt equivalent of the sodium salt (2) is formed as a result. In this embodiment, suitable temperatures, concentrations of potassium hydroxide and washing solvents are those described as suitable for sodium hydroxide hereinbefore.
  • Step c) Adjustment of the aqueous solution to pH 6 - 11 is suitably carried out by addition of hydrochloric acid, for example 0.02 to IM aqueous hydrochloric acid.
  • the solution is adjusted to pH 8-11.
  • the solution is adjusted to pH 9- 11, for example about pH 9-10.5.
  • the solution is adjusted to about pH 9-10.5 using ⁇ O.IM hydrochloric acid.
  • the solution is adjusted to about pH 10.5 using about 0.1M hydrochloric acid.
  • Preferably the solution is adjusted to about pH9, suitably using 0.02M aqueous hydrochloric acid.
  • Other inorganic acids known in the art may also be used, provided the calcium salt of the inorganic acid is water soluble so that it is not precipitated in Step f).
  • the water miscible organic solvent (and residual amounts of any organic solvent used as a wash in step b) above), may generally be removed by distillation, conveniently carried out under vacuum.
  • the distillation is suitably carried out for example using a vacuum of ⁇ 55 mBar, and a temperature of ⁇ 45 °C.
  • the vacuum is about 52 mBar and the temperature is about 33°C. It will be appreciated by those skilled in the art that water may be azeotropically removed with the acetonitrile during the distillation and that it may therefore be desirable to add further water to the mixture during the distillation process.
  • a suitable method for carrying out the distillation is provided in the accompanying non-limiting Example.
  • Step e) Filtration of the mixture resulting from step d) removes any unreacted starting material or insoluble impurities which may have precipitated during the distillation process of step d). It will be appreciated that water may be used to wash the filter. Any filter known in the art to be suitable may be used. Conveniently at a manufacturing scale, a GaF filter may be used (for example, a GAF filter E6-1825, manufactured by "Haywood Industrial Products). It will be appreciated that this filtration is not always necessary and may be omitted.
  • the water soluble calcium salt is suitably any such salt whose counter-ion forms a water soluble salt with sodium, such that it is easily removed by washing the product after isolation in step g).
  • Suitable water soluble calcium salts include calcium chloride, calcium bromide and calcium acetate. More suitably, calcium chloride or calcium bromide is used.
  • the water soluble calcium salt is calcium chloride.
  • calcium chloride is conveniently provided as its dihydrate form and is suitably added to the filtrate as an aqueous solution. A slight excess of calcium chloride may be used, for example 0.6 molar equivalents compared to the Agent.
  • the calcium chloride is suitably added as a 0.1 g/ml aqueous solution.
  • the temperature of the reaction mixture is suitably maintained at 32-43°C, more suitably at approximately 40°C, during the addition process.
  • the rate of addition of calcium chloride may be adjusted such that the temperature of the reaction mixture is so maintained.
  • the calcium chloride is added over 15-30 minutes.
  • the mixture may be maintained at the addition temperature for a period (herein referred to as the 'hold time') before isolation of the calcium salt.
  • the hold time is at least 10 minutes. In another embodiment the hold time is at least 20 minutes. In a further embodiment the hold time is at least 30 minutes.
  • Isolation of the calcium salt may conveniently be carried out by filtration, conveniently at about 20°C (herein referred to as the "filtration temperature").
  • the mixture may be maintained at the filtration temperature for a period before filtration is carried out, for example for 10 to 20 minutes, conveniently for 15 minutes. It will be appreciated that water may be used to wash the filtrate.
  • an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of ( ⁇ )-(6- ⁇ 2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl ⁇ (4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at an elevated temperature; b) reaction of the resulting solution with aqueous sodium hydroxide; c
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of ( ⁇ )-(6- ⁇ 2-[4-(4-fluorophenyl)-6-isopropyl-2-
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
  • step b [methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g) as described in any aspect or embodiment hereinbefore or hereinafter, wherein, in step b), potassium hydroxide is used instead of sodium hydroxide.
  • the reduced number of steps in the process of the invention results in fewer operational processes during the manufacture, which may translate into a more robust process.
  • the reduced number of steps in the process of the invention involves reduced handling of material, which may result in less opportunity for degradation or contamination of the product. Also, certain chemical reagents are no longer required and the total amount of waste and/or effluent is reduced, providing an environmental benefit.
  • a further aspect of the invention provides the compound (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid calcium salt made by the process steps a) to g) as hereinbefore described.
  • a further aspect of the invention provides the compound (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid calcium salt made by the process steps a') to g) as described in any aspect or embodiment hereinbefore.
  • Another aspect of the invention provides a product obtained by the process of the present invention.
  • step f a suitable magnesium salt in step f
  • a suitable magnesium salt in step f such as magnesium chloride
  • Such a salt thus obtained could be converted by processes known in the art into the calcium salt (1).
  • a process for making the magnesium salt of the Agent comprising the steps a) to g) as hereinbefore described wherein, in step f) a water soluble magnesium salt (such as magnesium chloride) is added instead of a water soluble calcium salt (such as calcium chloride).
  • Example 2 The synthesis of analogues of BEM is illustrated below for the iso-propyl analogue. Other analogues can be made by similar procedures.
  • the batch was cooled to 25°C over 30 minutes, 0-5°C over 30 minutes, then chilled to -8°C over 20 minutes and kept at this temperature for 30 minutes.
  • reaction mixture was agitated at -60°C for 30 minutes followed by the dropwise addition of triethylamine (26.36 g, 261 mmol) over 30 minutes, allowing the internal temperature to rise to -50°C.
  • the reaction mixture was then allowed to warm to 25°C evenly over 75 minutes.
  • the resulting slurry was stirred at 25°C for 30 minutes, then water (77 mL) was added and the mixture agitated for 30 minutes.
  • the aqueous layer was separated and the pH checked (pH should be between 7.5 and 8.5).
  • the resulting organic portion was washed with water (23.3 mL) and the organic portion separated for vacuum distillation at 150 mbar. Distillation was continued until -350 mL of toluene had been removed.
  • Toluene (350 mL) was added to the flask and the vacuum distillation repeated at 150 mbar to remove -350 mL of toluene.
  • the resulting solution was transferred to a flask containing activated 4 angstrom molecular sieves and left at ambient temperature overnight. This solution was used directly for the coupling stage.
  • Toluene (125 ml) was then added and the mixture stirred at 40°C for 30 minutes before it was allowed to settle for 1 hour at 40°C.
  • the aqueous phase was then separated from the organic phase at 40°C.
  • the aqueous phase was distilled under reduced pressure (53mBar, ⁇ 40°C) until the volume was reduced tol35 ml.
  • the resulting aqueous solution was filtered through a filter pad and the filter washed with water and combined with the aqueous reaction solution, such that the total volume of the resulting aqueous solution was 170 ml.
  • This solution was heated to 40°C before addition of a solution of calcium chloride di-hydrate (3.05g) in water (29.5ml) over 20min, maintaining the reaction mixture at 38-41°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An improved process for manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, Formula (1), which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis, is described.

Description

IMPROVED PRODUCTION OF ROSUVASTATIN CALCIUM SALT
This invention concerns improvements to a chemical process, particularly a chemical process for manufacture of (£)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (1) (illustrated below), which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.
Figure imgf000002_0001
The sodium salt (2) and calcium salt (1) of compound (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid (hereinafter referred to as the 'Agent') were disclosed in European Patent 0521471. This patent also describes a process for the synthesis of the calcium salt (1), via the sodium salt (2), as shown in Scheme 1 below. The calcium salt thus formed is then collected and dried and may be processed further as required.
diethylmethoxyborane sodium borohydride
Figure imgf000003_0001
Ca2+ Calcium chloride
Figure imgf000003_0003
Figure imgf000003_0002
Scheme 1
Our International Patent Application WO 00/49014 describes an alternative route to the calcium salt (1), also via the sodium salt (2), from the compound BEM (3), which is exemplified as shown in Scheme 2 below:
Figure imgf000003_0004
I. NaCI, HCI. -5 deg C
2.methylamine water
Figure imgf000003_0005
Figure imgf000003_0006
Scheme 2 As described in WO 00/49014, the transformation from BEM (3) to the calcium salt (1) may be carried out via the methylamine salt (4) as shown in Scheme 2. Isolation of this intermediate crystalline methylamine salt allows purification by recrystallisation before final formation of the (amorphous) calcium salt. Our co-pending application WO 2004/014872 describes an improved process for isolation of the calcium salt from a water soluble salt, such as the transformation from the methylamine salt (4) to the calcium salt (1) in Scheme 2 above, wherein the improvement comprises adjustment of time and temperature parameters such that optimal physical form of the product is obtained. We have surprisingly discovered an improvement to the process of manufacturing the calcium salt, which results in improved overall yield and a reduced number of steps to effect the transformation from BEM (3) to the calcium salt (1), whereby the step of isolating an intermediate salt is avoided. Surprisingly the quality of the resultant calcium salt product is not adversely affected. The process of this invention is also applicable to alkyl esters of the agent other than the tertiary-butyl ester, BEM (3).
According to the present invention there is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): a) reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in a water miscible organic solvent with aqueous acid at an elevated temperature; b) reaction of the resulting solution with an aqueous alkali metal hydroxide and optionally washing the resulting aqueous alkali metal salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to between pH6 and pHl 1 ; d) removal of the water miscible organic solvent; e) optional filtration of the resulting mixture; f) addition of a water soluble calcium salt to the filtrate so as to form (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5- dihydroxyhept-6-enoic acid calcium salt; and g) isolation of the product of step f). It will be appreciated that this process achieves the conversion of the ester to the calcium salt (1) without isolation of an intermediate salt of the acid.
Step a) Suitable solvents for step a) are in general any water miscible organic solvent; for example solvents such as acetonitrile and acetone. A preferred solvent is acetonitrile.
Suitable aqueous acids are acids whose calcium salt is water soluble so that it is not precipitated in Step f). In one embodiment, the aqueous acid is hydrochloric acid. In one aspect of this embodiment, the aqueous hydrochloric acid is approximately 0.1M. In another aspect of this embodiment, the aqueous hydrochloric acid is < about 0.1M. Conveniently the aqueous hydrochloric acid is <0.05M, for example 0.02M.
Suitably, the reaction of the (l-6C)alkyl ester of the Agent with aqueous acid is carried out between 30 and 50°C, conveniently between 35 and 40°C.
More suitably, the (l-6C)alkylester of the Agent, dissolved in acetonitrile at 35°C is reacted with aqueous hydrochloric acid at 35 °C. .
Suitable (l-6C)alkyl esters of the Agent are, for example methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, pentyl or hexyl esters. BEM is a preferred example of a (1- 6C)alkyl ester of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid. The starting material BΕM may be made as described in WO 00/49014. Analogues of
BΕM may be made by analogous processes, as illustrated in the Examples hereinafter.
Step b)
Step b) may be carried out at a temperature of between approximately 10°C and approximately 40°C. Conveniently, step b) is carried out at ambient temperature, which will generally be understood to mean 20-25 °C, conveniently approximately 25 °C.
Suitably the aqueous alkali metal hydroxide is aqueous potassium hydroxide or aqueous sodium hydroxide.
In one embodiment, the aqueous alkali metal hydroxide is sodium hydroxide. In this embodiment, suitably the aqueous sodium hydroxide is about IM and sufficient quantity is added to form the sodium salt (2). It will be appreciated that the sodium salt (2) is not isolated and that the product of step b) is an aqueous sodium salt solution. It will also be appreciated that this aqueous sodium salt solution also contains acetonitrile. The aqueous alkali metal salt solution may be washed with toluene, or another suitable organic solvent to remove unreacted (l-6C)alkyl ester of the Agent, such as BEM (3), or other unwanted minor components if required, prior to carrying out step c). Suitable organic solvents for this washing step are in general organic solvents which are immiscible in water but miscible with the water miscible organic solvent used in step a). When the water miscible organic solvent in step a) is acetonitrile, suitable organic solvents for the washing step are ester, ether and hydrocarbon solvents known in the art. Examples of such suitable solvents are xylene (hydrocarbon solvent), methyl-t-butylether (MTBE) (ether solvent) and ethyl acetate (ester solvent). The toluene or other suitable organic solvent may conveniently be removed from the process by phase separation. Any solvent remaining after phase separation may be removed in Step d). Preferably the solvent is toluene.
In one embodiment, the aqueous alkali metal salt is an aqueous sodium salt. In this embodiment, in step b), the aqueous sodium salt solution is washed with a suitable organic solvent. In one aspect of this embodiment, the aqueous sodium salt solution is washed with toluene, xylene, MTBE or ethyl acetate. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with toluene or xylene. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with toluene. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with MTBE. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with ethyl acetate.
In another embodiment, in step b), the aqueous sodium salt solution is not washed with a suitable organic solvent.
In an alternative embodiment of this invention, the aqueous alkali metal hydroxide is potassium hydroxide. It will be appreciated that in this embodiment, the potassium salt equivalent of the sodium salt (2) is formed as a result. In this embodiment, suitable temperatures, concentrations of potassium hydroxide and washing solvents are those described as suitable for sodium hydroxide hereinbefore.
Step c) Adjustment of the aqueous solution to pH 6 - 11 is suitably carried out by addition of hydrochloric acid, for example 0.02 to IM aqueous hydrochloric acid. In one embodiment, the solution is adjusted to pH 8-11. In another embodiment, the solution is adjusted to pH 9- 11, for example about pH 9-10.5. Suitably, the solution is adjusted to about pH 9-10.5 using ≤O.IM hydrochloric acid. More suitably, the solution is adjusted to about pH 10.5 using about 0.1M hydrochloric acid. Preferably the solution is adjusted to about pH9, suitably using 0.02M aqueous hydrochloric acid. Other inorganic acids known in the art may also be used, provided the calcium salt of the inorganic acid is water soluble so that it is not precipitated in Step f).
Step d)
The water miscible organic solvent (and residual amounts of any organic solvent used as a wash in step b) above), may generally be removed by distillation, conveniently carried out under vacuum.
When the water miscible organic solvent is acetonitrile, the distillation is suitably carried out for example using a vacuum of <55 mBar, and a temperature of <45 °C.
Conveniently, the vacuum is about 52 mBar and the temperature is about 33°C. It will be appreciated by those skilled in the art that water may be azeotropically removed with the acetonitrile during the distillation and that it may therefore be desirable to add further water to the mixture during the distillation process. A suitable method for carrying out the distillation is provided in the accompanying non-limiting Example.
Step e) Filtration of the mixture resulting from step d) removes any unreacted starting material or insoluble impurities which may have precipitated during the distillation process of step d). It will be appreciated that water may be used to wash the filter. Any filter known in the art to be suitable may be used. Conveniently at a manufacturing scale, a GaF filter may be used (for example, a GAF filter E6-1825, manufactured by "Haywood Industrial Products). It will be appreciated that this filtration is not always necessary and may be omitted.
Step f)
Generally, the water soluble calcium salt is suitably any such salt whose counter-ion forms a water soluble salt with sodium, such that it is easily removed by washing the product after isolation in step g). Suitable water soluble calcium salts include calcium chloride, calcium bromide and calcium acetate. More suitably, calcium chloride or calcium bromide is used.
In one embodiment, the water soluble calcium salt is calcium chloride. In this embodiment, calcium chloride is conveniently provided as its dihydrate form and is suitably added to the filtrate as an aqueous solution. A slight excess of calcium chloride may be used, for example 0.6 molar equivalents compared to the Agent. The calcium chloride is suitably added as a 0.1 g/ml aqueous solution. The temperature of the reaction mixture is suitably maintained at 32-43°C, more suitably at approximately 40°C, during the addition process. The rate of addition of calcium chloride may be adjusted such that the temperature of the reaction mixture is so maintained. Suitably the calcium chloride is added over 15-30 minutes. The mixture may be maintained at the addition temperature for a period (herein referred to as the 'hold time') before isolation of the calcium salt. In one embodiment, the hold time is at least 10 minutes. In another embodiment the hold time is at least 20 minutes. In a further embodiment the hold time is at least 30 minutes.
Step g)
Isolation of the calcium salt may conveniently be carried out by filtration, conveniently at about 20°C (herein referred to as the "filtration temperature"). The mixture may be maintained at the filtration temperature for a period before filtration is carried out, for example for 10 to 20 minutes, conveniently for 15 minutes. It will be appreciated that water may be used to wash the filtrate.
According to the present invention there is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): a) reaction of tert-butvl (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetate (BEM) in acetonitrile with aqueous hydrochloric acid at an elevated temperature; b) reaction of the resulting solution with aqueous sodium hydroxide; c) adjustment of the pH of the resulting solution to between pH6 and pHl 1 ; d) removal of acetonitrile; e) filtration of the resulting mixture; f) addition of calcium chloride to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6- enoic acid calcium salt; and g) isolation of the product of step f).
In a further aspect of the invention there is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a), b) c), d), f) and g) as described hereinbefore.
According to the present invention is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at an elevated temperature; b) reaction of the resulting solution with aqueous sodium hydroxide; c) adjustment of the pH of the resulting solution to between pH6 and pHl 1 ; d) removal of acetonitrile; e) filtration of the resulting mixture; f) addition of calcium chloride to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid calcium salt; and g) isolation of the product of step f).
In a further aspect of the invention is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a'), b) c), d), f) and g) as described hereinbefore.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): a) reaction of tert-butyl (Ε)-(6- { 2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetate (BEM) in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH9 by addition of <0.05M aqueous hydrochloric acid; d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 °C; and g) isolation of the product of step f) by filtration at about 20°C.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-όC)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH9 by addition of <0.05M aqueous hydrochloric acid; d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): a) reaction of tert-butyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetate (BEM) in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{ 2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable hydrocarbon, ester or ether solvent; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to foιτιι (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with toluene, xylene, MTBE or ethylacetate; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with toluene; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and washing the resulting aqueous sodium salt solution with a suitable hydrocarbon, ester or ether solvent; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and washing the resulting aqueous sodium salt solution with toluene, xylene, MTBE or ethylacetate; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and washing the resulting aqueous sodium salt solution with toluene; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0. IM aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43°C; and g) isolation of the product of step f) by filtration at about 20°C.
In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g) as described in any aspect or embodiment hereinbefore or hereinafter, wherein, in step b), potassium hydroxide is used instead of sodium hydroxide.
The process of the invention generally results in improved overall percentage yield
(starting from BΕM or other (l-6C)alkyl ester) and a reduced number of steps in comparison with the processes known in the art. It will be appreciated that a higher percentage yield may provide a significant cost benefit when manufacture is taking place on a commercial scale.
The reduced number of steps in the process of the invention results in fewer operational processes during the manufacture, which may translate into a more robust process. The reduced number of steps in the process of the invention involves reduced handling of material, which may result in less opportunity for degradation or contamination of the product. Also, certain chemical reagents are no longer required and the total amount of waste and/or effluent is reduced, providing an environmental benefit.
A further aspect of the invention provides the compound (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid calcium salt made by the process steps a) to g) as hereinbefore described.
A further aspect of the invention provides the compound (E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- enoic acid calcium salt made by the process steps a') to g) as described in any aspect or embodiment hereinbefore.
Therefore a further aspect of the invention provides a product obtainable by the process of the present invention.
Another aspect of the invention provides a product obtained by the process of the present invention.
It will be appreciated that the process of the current invention could be applied to make alternative salts of the Agent, such as the magnesium salt by use of a suitable magnesium salt in step f), such as magnesium chloride. Such a salt thus obtained could be converted by processes known in the art into the calcium salt (1). Thus in another aspect of the invention, is provided a process for making the magnesium salt of the Agent, comprising the steps a) to g) as hereinbefore described wherein, in step f) a water soluble magnesium salt (such as magnesium chloride) is added instead of a water soluble calcium salt (such as calcium chloride).
The invention is further illustrated by the following examples.
Example 1
BEM (20.0g) was dissolved in acetonitrile (140ml) at 40°C, then cooled to 35°C before gradual addition of hydrochloric acid (0.02M, 35ml) at 35°C. The resulting solution was stirred at 35°C until the reaction was complete then cooled to 25°C. Sodium hydroxide (1.0M, 38ml) was added at 25°C and the resulting mixture stirred at this temperature until the reaction was complete. Aqueous hydrochloric acid (IM) was added to adjust the pH of the solution to pH9. The solution was distilled under reduced pressure (52mBar, <40°C) until approximately 100ml of acetonitrile/water had been removed. Water (100ml) was added and distillation continued until a further 100ml of acetonitrile/water had been removed. The resulting mixture was filtered through a filter pad, the filter washed with water (30ml) and the filtrates heated to 40°C before addition of a solution of calcium chloride dihydrate (3.07g) in water (29.5ml) over 20min, maintaining the reaction mixture at 38-41°C. The reaction mixture was stirred for a further 15min at 40°C, then cooled to 20°C and stirred at this temperature for a further 15min. The resulting suspension was filtered, washed with water (3 x 50ml) and dried to give (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (15.8g, 84% yield).
Example 2 The synthesis of analogues of BEM is illustrated below for the iso-propyl analogue. Other analogues can be made by similar procedures.
iso-Propyl (E)-(6-{2-r4-(4-fluorophenyl)-6-isopropyl-2-rmethyl(methvIsulfonyI)amino1 pyrimidin-5-yllvinyl}(4R,6S)-2,2-dimethyiri,31dioxan-4-yl)acetate Sodium bis(trimethylsilyl)amide (80.47 mL, l.OM in THF) was added dropwise to a cooled solution of diphenyl [4-(4-fluoropheny)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-ylmethyl] phosphine oxide (40.43 g, 75 mmol) in THF (477.1 mL) at -65°C over 30 minutes, maintaining the temperature at -65°C. Isopropyl- 2-[(4R,6S)-6-formyl-2,2- dimethyl-l,3-dioxan-4-yl} acetate in toluene (21.68 g) was added dropwise to the solution over 35 minutes, maintaining the temperature at -65°C. The contents of the vessel were kept at -65°C for 15 minutes, then allowed to warm evenly to 10°C over 80 minutes. Water (40.4 mL) followed by acetic acid (6.87 g, 114 mmol) were added to give a two phase light yellow solution. The batch was then distilled at atmospheric pressure to remove ~ 485 mL of distillates. This solution was washed sequentially with water (84 mL), 7.0% w/w sodium bicarbonate (92.6 g), 1.8% w/w sodium bicarbonate (91.1 g) and water (63.5 mL). The resulting organic phase was distilled under vacuum at 270 mbar to leave ~ 95 mL of solution in the distillation flask (removing ~ 229mL of distillates). Methanol (202 mL) at 50°C was charged to the flask and the solution distilled at atmospheric pressure, removing ~ 134 mL of distillates. A further portion of methanol (229 mL) at 50°C was added to the solution and the batch cooled to 40°C over 30 minutes. The batch was cooled to 25°C over 30 minutes, 0-5°C over 30 minutes, then chilled to -8°C over 20 minutes and kept at this temperature for 30 minutes. The solid was collected by vacuum filtration, washed with 2 portions of cooled (- 8°C) methanol (2 x 80.6 mL) then dried in a vacuum oven at 50°C, 200 mbar, yield = 28.9 g (68.3%). 1H NMR 5: 1.15 (q, 1H) 1.24 (dd, 6H) 1.27 (dd, 6H) 1.40 (s, 3H) 1.49 (s, 3H) 1.55 (dt, 1H) 2.34 (dd, 1H) 2.50 (dd, 1H) 3.38 (spt, 1H) 3.51 (s, 3H) 3.57 (s, 3H) 4.32 (m, 1H) 4.43 (m, 1H) 5.04 (spt, 1H) 5.47 (dd, 1H) 6.52 (d, 1H) 7.08 (t, 2H) 7.65 (dd, 2H) Isopropyl- 2-r(4R.6S)-6-formyl-2.2-dimethyl-L3-dioxan-4-yl|acetate Chlorine gas (2469.6 mL, 118 mmol) was charged to toluene (373.3 mL, 16 rel vol) at -60°C. Dimethyl sulphide (11.67 mL, 121 mmol) was then added dropwise to the cooled solution over 30 minutes, keeping the contents at -60°C. After 30 minutes at this temperature, iso- propyl 2-[(4R,6S)-6-hydroxymethyl-2,2-dimethyl-l,3-dioxan-4-yl} acetate (24.56 g, 95 mmol) in toluene (46.7 mL) was added dropwise to the vessel over 30 minutes, maintaining the internal temperature at -60°C. The reaction mixture was agitated at -60°C for 30 minutes followed by the dropwise addition of triethylamine (26.36 g, 261 mmol) over 30 minutes, allowing the internal temperature to rise to -50°C. The reaction mixture was then allowed to warm to 25°C evenly over 75 minutes. The resulting slurry was stirred at 25°C for 30 minutes, then water (77 mL) was added and the mixture agitated for 30 minutes. The aqueous layer was separated and the pH checked (pH should be between 7.5 and 8.5). The resulting organic portion was washed with water (23.3 mL) and the organic portion separated for vacuum distillation at 150 mbar. Distillation was continued until -350 mL of toluene had been removed. Toluene (350 mL) was added to the flask and the vacuum distillation repeated at 150 mbar to remove -350 mL of toluene. The resulting solution was transferred to a flask containing activated 4 angstrom molecular sieves and left at ambient temperature overnight. This solution was used directly for the coupling stage.
Iso-propyl 2-r(4R.6S)-6-hydroxymethyl-2.2-dimethyl- 3-dioxan-4-yl}acetate This compound may be made using the procedures described in EP0319847. Analogues with different ester groups R may be made by a similar method.
Diphenyl r4-(4-fluoropheny)-6-isopropyl-2-rmethyl(methylsulfonyl)aminolpyrimidin-5- ylmethyll phosphine oxide
This compound can be made as described in Patent Application WO00/49014
Example 3: Procedure using wash in step b)
BEM (20.0g) was dissolved in acetonitrile (140ml) at 40°C, then cooled to 35°C before gradual addition of hydrochloric acid (0.02M, 35ml) at 35°C. The resulting solution was stirred at 35°C until the reaction was complete then cooled to 25°C. Further acetonitrile (8 ml) was added before sodium hydroxide (l.OM, 38ml) was added at 25°C and the resulting mixture stirred at this temperature until the reaction was complete. Aqueous hydrochloric acid (0.1M) was added to adjust the pH of the solution to approximately pH10.5. Water was added so that the combined volume of water and hydrochloric acid (0.1M) (from the previous pH adjustment step) added was 100ml. Toluene (125 ml) was then added and the mixture stirred at 40°C for 30 minutes before it was allowed to settle for 1 hour at 40°C. The aqueous phase was then separated from the organic phase at 40°C. The aqueous phase was distilled under reduced pressure (53mBar, <40°C) until the volume was reduced tol35 ml. The resulting aqueous solution was filtered through a filter pad and the filter washed with water and combined with the aqueous reaction solution, such that the total volume of the resulting aqueous solution was 170 ml. This solution was heated to 40°C before addition of a solution of calcium chloride di-hydrate (3.05g) in water (29.5ml) over 20min, maintaining the reaction mixture at 38-41°C.
The reaction mixture was stirred for a further 15 min at 40°C, then cooled to 20°C and stirred at this temperature for a further 15min. The resulting suspension was filtered, washed with water (3 x 53ml) and dried to give (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt (14.7g @100% strength, 85% yield).
1H NMR 5: 1.21 (d+d, 6H) 1.32 (dt, IH) 1.51 (dt, IH) 2.00 (dd, IH) 2.14 (dd, IH) 3.42 (spt, IH)* 3.45 (s, 3H) 3.54 (s, 3H) 3.77 (m, IH) 4.21 (q, IH) 5.53 (dd, IH) 6.51 (dd, IH) 7.27 (t, 2H) 7.71 (dd, 2H) [The IH NMR was carried out as a 3% w/v solution in d6 DMSO (where d5 DMSO=2.5 lδ)] . ^partially obscured

Claims

Claims
1. A process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): a) reaction of a (l-6C)alkyl ester of (Ε)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[l,3]dioxan-4- yl)acetic acid in a water miscible organic solvent with aqueous acid at an elevated temperature; b) reaction of the resulting solution with an aqueous alkali metal hydroxide and optionally washing the resulting aqueous alkali metal salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to between pH6 and pHl 1 ; d) removal of the water miscible organic solvent; e) optional filtration of the resulting mixture; f) addition of a water soluble calcium salt to the filtrate so as to form (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5- dihydroxyhept-6-enoic acid calcium salt; and g) isolation of the product of step f).
2. A process as claimed in Claim 1 wherein the water miscible organic solvent is acetonitrile.
3. A process as claimed in Claim 1 or Claim 2 wherein in step a) the aqueous acid is hydrochloric acid.
4 A process as claimed in any one of the preceding claims wherein step b) comprises: reaction of the resulting solution with aqueous sodium hydroxide and washing the resulting aqueous sodium salt solution with a suitable hydrocarbon, ester or ether solvent.
5. A process as claimed in any one of the preceding claims wherein the aqueous sodium salt solution is washed with toluene, xylene, MTBE or ethyl acetate.
6. A process as claimed in Claim 5 wherein the aqueous sodium salt solution is washed with toluene.
7. A process as claimed in any one of the preceding claims wherein the (l-6C)alkyl ester is the tert-butyl ester.
8. A process as claimed in any one of the preceding claims wherein step a) is carried out at 35-40°C.
9. A process as claimed in any one of the preceding claims wherein step b) is carried out at ambient temperature.
10. A process as claimed in Claim 1 wherein in step b), the aqueous alkali metal hydroxide is potassium hydroxide.
11. A process as claimed in any one of the preceding claims wherein step c) comprises adjustment of the pH of the solution to about pH9-10.5 by addition of aqueous hydrochloric acid.
12 A process as claimed in any one of the preceding claims wherein step d) is carried out at a pressure of <55mBar and a temerature of <45°C.
13. A process as claimed in any one of the preceding claims wherein in step f) the water soluble calcium salt is calcium chloride.
14. A process as claimed in any one of the preceding claims wherein in step f) the calcium salt is added at 32-43 °C.
15. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt made by the process steps a) to g) as claimed in Claim 1.
16. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulf onyl)amino]pyrimidin-5-yl] (3R,5S)-3 ,5-dihydroxyhept-6-enoic acid calcium salt made by the process steps a) to g) as claimed in Claim 7.
PCT/GB2004/002373 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt WO2004108691A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP04735910A EP1633727B1 (en) 2003-06-05 2004-06-03 Improved production of the rosuvastatin calcium salt
DE602004026576T DE602004026576D1 (en) 2003-06-05 2004-06-03 IMPROVED METHOD FOR THE PRODUCTION OF ROSUVASTATIN CALCIUM SALT
US10/558,390 US8063213B2 (en) 2003-06-05 2004-06-03 Production of rosuvastatin calcium salt
AU2004245291A AU2004245291B2 (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt
KR1020057023329A KR101099934B1 (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt
CA2527314A CA2527314C (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt
MXPA05013128A MXPA05013128A (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt.
BRPI0410922A BRPI0410922B8 (en) 2003-06-05 2004-06-03 process for forming a compound
JP2006508394A JP4651615B2 (en) 2003-06-05 2004-06-03 Improved manufacture of rosuvastatin calcium salt
NZ543962A NZ543962A (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt
AT04735910T ATE464297T1 (en) 2003-06-05 2004-06-03 IMPROVED METHOD FOR PRODUCING ROSUVASTATIN CALCIUM SALT
IL172075A IL172075A (en) 2003-06-05 2005-11-21 Production of rosuvastatin calcium salt
NO20055730A NO332971B1 (en) 2003-06-05 2005-12-05 Improved production of rosuvastatin calcium salt
IS8217A IS2751B (en) 2003-06-05 2006-01-02 Improved output @ @ rósúvastatínkalsíumsalts
HK06107580.5A HK1087405A1 (en) 2003-06-05 2006-07-05 Improved production of the rosuvastatin calcium salt

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0312896.4 2003-06-05
GBGB0312896.4A GB0312896D0 (en) 2003-06-05 2003-06-05 Chemical process
GBGB0324793.9A GB0324793D0 (en) 2003-06-05 2003-10-24 Chemical process
GB0324793.9 2003-10-24

Publications (1)

Publication Number Publication Date
WO2004108691A1 true WO2004108691A1 (en) 2004-12-16

Family

ID=33512687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002373 WO2004108691A1 (en) 2003-06-05 2004-06-03 Improved production of rosuvastatin calcium salt

Country Status (26)

Country Link
US (1) US8063213B2 (en)
EP (1) EP1633727B1 (en)
JP (1) JP4651615B2 (en)
KR (1) KR101099934B1 (en)
CN (1) CN100422157C (en)
AR (1) AR044773A1 (en)
AT (1) ATE464297T1 (en)
AU (1) AU2004245291B2 (en)
BR (1) BRPI0410922B8 (en)
CA (1) CA2527314C (en)
CO (1) CO5640116A2 (en)
DE (1) DE602004026576D1 (en)
ES (1) ES2341858T3 (en)
GB (2) GB0312896D0 (en)
HK (1) HK1087405A1 (en)
IL (1) IL172075A (en)
IS (1) IS2751B (en)
MX (1) MXPA05013128A (en)
MY (1) MY140820A (en)
NO (1) NO332971B1 (en)
NZ (1) NZ543962A (en)
RU (1) RU2361864C2 (en)
SA (1) SA04250223B1 (en)
TW (1) TWI341310B (en)
UY (1) UY28341A1 (en)
WO (1) WO2004108691A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042522A1 (en) * 2003-10-24 2005-05-12 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7129352B2 (en) 2000-02-15 2006-10-31 Astrazeneca Ab Crystalline salts of 7-′4-(4-fluorophenyl) -6-isopropyl-2-′methyl (methylsulfonyl) amino!pyrimidin-5-yl!- (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid
WO2007000121A1 (en) * 2005-06-29 2007-01-04 Zentiva, A.S. A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2007022366A3 (en) * 2005-08-16 2007-05-31 Teva Pharma Rosuvastatin calcium with a low salt by-product content
WO2007119085A1 (en) * 2006-04-13 2007-10-25 Egis Gyógyszergyár Nyilvánosan Mukodo Reszvenytársaság Rosuvastatin zinc salt
US7304156B2 (en) 2001-07-13 2007-12-04 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US7416865B2 (en) 2000-05-09 2008-08-26 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7442811B2 (en) 2002-06-17 2008-10-28 Astrazeneca Uk Limited Process for the preparation of dioxane acetic acid esters
US7511140B2 (en) 2002-08-13 2009-03-31 Astrazeneca Ab Process for preparing the calcium salt of rosuvastatin
WO2009047577A1 (en) * 2007-10-12 2009-04-16 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Process for preparation of rosuvastatin zinc salt
US7524955B2 (en) 2002-12-16 2009-04-28 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates
WO2009156173A1 (en) 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
US7642363B2 (en) 2000-07-19 2010-01-05 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,3-dioxane-4-YL) acetic acid derivatives
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
US7718812B2 (en) 2001-12-27 2010-05-18 Astrazeneca Uk Limited Process for the preparation of 2-(6-substituted-1,3-dioxane-4-yl) acetic acid derivates
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
US7932263B2 (en) 2003-09-26 2011-04-26 Astrazeneca Ab Therapeutic treatment
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2361906A1 (en) 2004-12-24 2011-08-31 AstraZeneca UK Limited Process for preparing rosuvastatin
WO2011132172A1 (en) 2010-04-23 2011-10-27 Ranbaxy Laboratories Limited NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
US8063211B2 (en) * 2005-02-22 2011-11-22 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US8063213B2 (en) 2003-06-05 2011-11-22 Astrazeneca Uk Limited Production of rosuvastatin calcium salt
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
EP1915349B1 (en) 2005-06-24 2015-12-09 LEK Pharmaceuticals d.d. Process for preparing pure amorphous rosuvastatin calcium

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CN105753834B (en) * 2016-03-25 2018-08-21 河南师范大学 A kind of synthetic method of rosuvastain calcium key chiral intermediate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
WO2000042024A1 (en) * 1999-01-09 2000-07-20 Astrazeneca Ab Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
WO2000049014A1 (en) * 1999-02-17 2000-08-24 Astrazeneca Ab Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (en) 1987-12-08 1989-06-22 Hoechst Ag METHOD FOR PRODUCING OPTICALLY ACTIVE 3-DESMETHYLMEVALONIC ACID DERIVATIVES AND INTERMEDIATE PRODUCTS
KR900701778A (en) 1988-10-06 1990-12-04 예안 크라머, 한스 루돌프 하우스 Pyrimidinyl-substituted hydroxy acids, lactones and esters, and pharmaceutical compositions containing them
US5026698A (en) 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DE59307409D1 (en) 1992-07-02 1997-10-30 Hoechst Ag Process for the preparation of (3R, 5S) 6-hydroxy-3,5-0-isopropylidene-3,5-dihydroxy-hexanoic acid tert-butyl ester
IL128862A (en) 1995-07-17 2007-12-03 Warner Lambert Co CRYSTALLINE [R-(R*R*)] - 2 - (4 - FLUOROPHENYL) - ??, Ó¬á - DELTA-DIHYDROXY - 5 - (1 - METHYLETHYL) - 3 - PHENYL - 4 - (PHENYLAMINO) CARBONYL] - 1H - PYRROLE - 1 - HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN)HYDRATE
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (en) 1995-11-28 1997-12-26 Oreal PROCESS FOR THE PREPARATION OF COMPOUNDS WITH A BETA-HYDROXY -DELTA-LACTONE GROUP ANALOGS OF (+) COMPACTIN AND (+) MEVINOLINE
PT907639E (en) 1996-06-24 2003-06-30 Novartis Ag POLYMORPHIC COMPOUNDS
CN1226296C (en) 1998-12-10 2005-11-09 钟渊化学工业株式会社 Process for preparing
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
CZ20021642A3 (en) 1999-11-17 2003-05-14 Teva Pharmaceutical Industries Ltd. Polymorphous forms of calcium atorvastatin
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (en) * 2000-07-19 2002-01-22 Dsm Nv Process for the preparation of 2- (6-substituted-1,3-dioxan-4-yl) acetic acid derivatives.
JP3737801B2 (en) 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ Pravastatin sodium substantially free of pravastatin lactone and epipravastatin, and a composition comprising the same
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
IL155890A0 (en) 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (en) 2001-03-09 2002-09-10 Synthon Bv A lactonization process.
IN190564B (en) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CZ20033329A3 (en) 2001-06-06 2004-11-10 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid HMGg CoA reductase inhibitors
CN1301977C (en) * 2001-07-13 2007-02-28 阿斯特拉曾尼卡英国有限公司 Preparation of aminopyrimidine compounds
IL160077A0 (en) 2001-08-16 2004-06-20 Teva Pharma Processes for preparing calcium salt forms of statins
CN1545502A (en) 2001-08-22 2004-11-10 �������⻯ѧƷ�ع����޹�˾ Process for the preparation of indole derivatives
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (en) 2002-04-09 2005-08-31 임광민 CHIRAL INTERMEDIATE, PROCESS FOR THE PRODUCTION THEREOF, AND PROCESS FOR THE PRODUCTION OF HMG-CoA REDUCTASE INHIBITOR
AU2003228010A1 (en) 2002-05-21 2003-12-02 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
HUP0500851A3 (en) 2002-12-10 2008-02-28 Ranbaxy Lab Ltd Process for the preparation of rosuvastatin
MXPA05006425A (en) * 2002-12-16 2005-08-19 Astrazeneka Uk Ltd Process for the preparation of pyrimidine compounds.
US8367848B2 (en) 2003-04-11 2013-02-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
AU2003247327A1 (en) 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005040134A1 (en) 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (en) 2003-11-11 2007-09-13 Ratiopharm Gmbh Process for the preparation of statins and tetrahydropyranone derivatives for use in the process
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US20050159615A1 (en) 2003-12-24 2005-07-21 Entire Interest. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (en) 2004-01-16 2005-08-17 Zentiva, A.S. Process for preparing hemicalcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
EP1709008A1 (en) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
US20080234302A1 (en) 2004-09-27 2008-09-25 Mohammad Rafeeq Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
EP1844021A1 (en) 2005-01-31 2007-10-17 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
WO2000042024A1 (en) * 1999-01-09 2000-07-20 Astrazeneca Ab Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
WO2000049014A1 (en) * 1999-02-17 2000-08-24 Astrazeneca Ab Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129352B2 (en) 2000-02-15 2006-10-31 Astrazeneca Ab Crystalline salts of 7-′4-(4-fluorophenyl) -6-isopropyl-2-′methyl (methylsulfonyl) amino!pyrimidin-5-yl!- (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid
US7416865B2 (en) 2000-05-09 2008-08-26 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7888083B2 (en) 2000-05-09 2011-02-15 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7732171B2 (en) 2000-05-09 2010-06-08 Astrazeneca Uk Limited Process for the preparation of dihydroxy esters and derivatives thereof
US7989643B2 (en) 2000-07-19 2011-08-02 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,3-dioxane-4-yl)acetic acid derivatives
US7642363B2 (en) 2000-07-19 2010-01-05 Astrazeneca Uk Ltd. Process for the preparation of 2-(6-substituted-1,3-dioxane-4-YL) acetic acid derivatives
US7816528B2 (en) 2001-07-13 2010-10-19 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US7304156B2 (en) 2001-07-13 2007-12-04 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US8614320B2 (en) 2001-07-13 2013-12-24 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US8222412B2 (en) 2001-07-13 2012-07-17 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
US7718812B2 (en) 2001-12-27 2010-05-18 Astrazeneca Uk Limited Process for the preparation of 2-(6-substituted-1,3-dioxane-4-yl) acetic acid derivates
US7442811B2 (en) 2002-06-17 2008-10-28 Astrazeneca Uk Limited Process for the preparation of dioxane acetic acid esters
US7511140B2 (en) 2002-08-13 2009-03-31 Astrazeneca Ab Process for preparing the calcium salt of rosuvastatin
US7842807B2 (en) 2002-08-13 2010-11-30 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
US7524955B2 (en) 2002-12-16 2009-04-28 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
US8273878B2 (en) 2002-12-16 2012-09-25 Astrazeneca Uk Limited Process for the preparation of pyrimidine compounds
US8063213B2 (en) 2003-06-05 2011-11-22 Astrazeneca Uk Limited Production of rosuvastatin calcium salt
US7932263B2 (en) 2003-09-26 2011-04-26 Astrazeneca Ab Therapeutic treatment
EP2272842A1 (en) * 2003-10-24 2011-01-12 AstraZeneca UK Limited Process for the manufacture of the calcium salt of rosuvastatin and crystalline intermediates thereof
WO2005042522A1 (en) * 2003-10-24 2005-05-12 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
US9371291B2 (en) 2003-10-24 2016-06-21 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
EP2361906A1 (en) 2004-12-24 2011-08-31 AstraZeneca UK Limited Process for preparing rosuvastatin
US8034932B2 (en) 2004-12-24 2011-10-11 Astrazeneca Uk Limited Chemical process
US8063211B2 (en) * 2005-02-22 2011-11-22 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
EP1915349B1 (en) 2005-06-24 2015-12-09 LEK Pharmaceuticals d.d. Process for preparing pure amorphous rosuvastatin calcium
WO2007000121A1 (en) * 2005-06-29 2007-01-04 Zentiva, A.S. A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
WO2007022366A3 (en) * 2005-08-16 2007-05-31 Teva Pharma Rosuvastatin calcium with a low salt by-product content
JP2009533412A (en) * 2006-04-13 2009-09-17 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ Rosuvastatin zinc salt
WO2007119085A1 (en) * 2006-04-13 2007-10-25 Egis Gyógyszergyár Nyilvánosan Mukodo Reszvenytársaság Rosuvastatin zinc salt
EA016141B1 (en) * 2006-04-13 2012-02-28 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Rosuvastatin zinc salt
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2009047577A1 (en) * 2007-10-12 2009-04-16 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Process for preparation of rosuvastatin zinc salt
US8765947B2 (en) 2008-05-27 2014-07-01 Changzhou Pharmaceutical Factory Preparation method of Rosuvastatin calcium and its intermediates
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2009156173A1 (en) 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
US20110245285A1 (en) * 2008-09-09 2011-10-06 Biocon Limited Process for preparation of rosuvastatin acetonide calcium
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
WO2011132172A1 (en) 2010-04-23 2011-10-27 Ranbaxy Laboratories Limited NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
WO2012011129A3 (en) * 2010-07-22 2012-03-15 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt

Also Published As

Publication number Publication date
JP2006526602A (en) 2006-11-24
CN1798741A (en) 2006-07-05
CA2527314A1 (en) 2004-12-16
NO20055730D0 (en) 2005-12-05
BRPI0410922B1 (en) 2016-02-23
TWI341310B (en) 2011-05-01
TW200510337A (en) 2005-03-16
RU2361864C2 (en) 2009-07-20
IS8217A (en) 2006-01-02
AU2004245291B2 (en) 2008-02-14
GB0324793D0 (en) 2003-11-26
AR044773A1 (en) 2005-10-05
AU2004245291A1 (en) 2004-12-16
EP1633727A1 (en) 2006-03-15
NO332971B1 (en) 2013-02-11
ES2341858T3 (en) 2010-06-29
CA2527314C (en) 2012-02-21
ATE464297T1 (en) 2010-04-15
US20080221323A1 (en) 2008-09-11
EP1633727B1 (en) 2010-04-14
IS2751B (en) 2011-09-15
KR101099934B1 (en) 2011-12-28
MY140820A (en) 2010-01-29
NO20055730L (en) 2005-12-27
US8063213B2 (en) 2011-11-22
HK1087405A1 (en) 2006-10-13
RU2005138370A (en) 2006-07-10
GB0312896D0 (en) 2003-07-09
DE602004026576D1 (en) 2010-05-27
NZ543962A (en) 2008-09-26
BRPI0410922B8 (en) 2021-05-25
JP4651615B2 (en) 2011-03-16
UY28341A1 (en) 2005-01-31
BRPI0410922A (en) 2006-06-27
KR20060017848A (en) 2006-02-27
CN100422157C (en) 2008-10-01
IL172075A (en) 2011-06-30
CO5640116A2 (en) 2006-05-31
SA04250223B1 (en) 2008-12-23
MXPA05013128A (en) 2006-03-16

Similar Documents

Publication Publication Date Title
EP1633727B1 (en) Improved production of the rosuvastatin calcium salt
AU760145B2 (en) Process for the production of tert-butyl (E)-(6-(2- (4-(4-fluorophenyl) -6-isopropyl-2-( methyl (methylsulfonyl) amino) pyrimidin-5-YL) vinyl)(4R, 6S)-2,2-dimethyl (1,3)dioxan-4-YL) acetate
AU2006268024B2 (en) Processes for the manufacture of rosuvastatin and intermediates
US7842807B2 (en) Process for preparing the calcium salt of rosuvastatin
WO2007000121A1 (en) A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
NO310819B1 (en) Chloropyrimide intermediates and process for their preparation
AU2010209650B2 (en) Key intermediates for the synthesis of Rosuvastatin or pharmaceutically acceptable salts thereof
EP2125754B1 (en) Process for preparation of rosuvastatin calcium
ZA200509539B (en) Improved production of rosuvastatin calcium salt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172075

Country of ref document: IL

Ref document number: 2004245291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/09539

Country of ref document: ZA

Ref document number: 5419/DELNP/2005

Country of ref document: IN

Ref document number: 200509539

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2527314

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12005502153

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 05122683

Country of ref document: CO

Ref document number: 543962

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/013128

Country of ref document: MX

Ref document number: 20048154822

Country of ref document: CN

Ref document number: 1020057023329

Country of ref document: KR

Ref document number: 2006508394

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004245291

Country of ref document: AU

Date of ref document: 20040603

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004245291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004735910

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005138370

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057023329

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004735910

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410922

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10558390

Country of ref document: US